Advertisement

Virchows Archiv

, Volume 456, Issue 1, pp 45–51 | Cite as

Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor κB expression

  • Ruchi Gupta
  • Radhika SrinivasanEmail author
  • Raje Nijhawan
  • Vanita Suri
Original Article

Abstract

Tissue transglutaminase 2 (TG2) is a recently identified molecule with multifunctional physiological roles. This is the first report of the expression of TG2 in cervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinoma (SCC). For comparison, the expression of p16, a known surrogate biomarker of HPV infection, was evaluated. The expression of nuclear factor kappa B (NF-κB), a molecule crucial to inflammation and neoplasia, was also determined to explore its possible linkage with TG2 expression. Twenty cases each with normal cervical histology, CIN1, CIN2, CIN3, and invasive SCC were analyzed for TG2, p16, and NF-κB expression by immunohistochemistry. Intergroup differences were analyzed by Friedman ANOVA. Cytoplasmic as well as nuclear TG2 expression was observed in the epithelial cells. As compared to normal controls, CIN1 showed markedly increased cytoplasmic TG2 expression (p = 0.006). In CIN2/3, additional nuclear TG2 expression was seen (p = 0.009 and 0.031, respectively). Marked extracellular stromal upregulation of TG2 was noted in CIN3/SCC versus normal controls (p = 0.054; p = 0.003). There was no relationship of TG2 with either p16 of NF-κB expression. Combining TG2 immunoreactivity with p16 increased the immunolabeling of dysplasia from 35% to 100% in CIN1, 45% to 60% in CIN2, and 60% to 85% in CIN3. TG2 serves as an additional biomarker for all grades of cervical dysplasia, especially for low-grade dysplasia.

Keywords

Tissue transglutaminase 2 CIN p16 Cervical cancer Nuclear factor κB Biomarker 

Notes

Conflict of interest statement

We declare that we have no conflict of interest.

References

  1. 1.
    Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC, Lyon IARC Press Cancer Base No. 5 version 2.0Google Scholar
  2. 2.
    Winer RL, Kiviat NB, Hughes JP et al (2005) Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191:731–738CrossRefPubMedGoogle Scholar
  3. 3.
    Castle PE, Ashfaq R, Ansari F et al (2005) Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett 229:245–252CrossRefPubMedGoogle Scholar
  4. 4.
    Peng X, Zhang Y, Zhang H et al (1999) Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett 446:35–39CrossRefPubMedGoogle Scholar
  5. 5.
    Boehm JE, Singh U, Combs C et al (2002) Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110. Rb J Biol Chem 277:20127–20130CrossRefGoogle Scholar
  6. 6.
    Mangala LS, Fok JY, Zorrilla-Calancha IR et al (2006) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459–2470CrossRefPubMedGoogle Scholar
  7. 7.
    Fok JY, Ekmekcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493–1503CrossRefPubMedGoogle Scholar
  8. 8.
    Yuan L, Siegel M, Choi K et al (2006) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563–2573CrossRefPubMedGoogle Scholar
  9. 9.
    Klaes R, Friedrich T, Spitkovsky D et al (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92:276–284CrossRefPubMedGoogle Scholar
  10. 10.
    Kang S, Kim J, Kim HB et al (2006) Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. Diagn Mol Pathol 15:74–82CrossRefPubMedGoogle Scholar
  11. 11.
    Kalof AN, Cooper K (2006) p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 13:190–194CrossRefPubMedGoogle Scholar
  12. 12.
    Ishikawa M, Fujii T, Saito M et al (2006) Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 16:347–353CrossRefPubMedGoogle Scholar
  13. 13.
    Masumoto N, Fujii T, Ishikawa M et al (2003) P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 34:778–783CrossRefPubMedGoogle Scholar
  14. 14.
    Jeon JH, Choi KH, Cho SY et al (2003) Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J 22:5273–5282CrossRefPubMedGoogle Scholar
  15. 15.
    Shishodia S, Aggarwal BB (2002) Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 35:28–40PubMedGoogle Scholar
  16. 16.
    Mann AP, Verma A, Sethi G et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa}B in cancer cells: delineation of a novel pathway. Cancer Res 66:8788–8795CrossRefPubMedGoogle Scholar
  17. 17.
    Spitkovsky D, Hehner SP, Hofmann TG et al (2002) The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem 277:25576–25582CrossRefPubMedGoogle Scholar
  18. 18.
    Fontaine V, van der Meijden E, de Graaf J et al (2000) A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 272:40–49CrossRefPubMedGoogle Scholar
  19. 19.
    Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049–3058CrossRefPubMedGoogle Scholar
  20. 20.
    Verma A, Wang H, Manavathi B et al (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66:10525–10533CrossRefPubMedGoogle Scholar
  21. 21.
    Mehta K, Fok JY, Mangala LS (2006) Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci 11:173–185CrossRefPubMedGoogle Scholar
  22. 22.
    Hettasch JM, Bandarenko N, Burchette JL et al (1996) Tissue transglutaminase expression in human breast cancer. Lab Invest 75:637–645PubMedGoogle Scholar
  23. 23.
    Zemskov EA, Janiak A, Hang J et al (2006) The role of tissue transglutaminase in cell–matrix interactions. Front Biosci 11:1057–1076CrossRefPubMedGoogle Scholar
  24. 24.
    Akimov SS, Krylov D, Fleischman LF et al (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148:825–838CrossRefPubMedGoogle Scholar
  25. 25.
    Akimov SS, Belkin AM (2001) Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98:1567–1576CrossRefPubMedGoogle Scholar
  26. 26.
    Dardik R, Inbal A (2006) Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 312:2973–2982CrossRefPubMedGoogle Scholar
  27. 27.
    Yildiz IZ, Usubutun A, Firat P et al (2007) Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 203:445–449CrossRefPubMedGoogle Scholar
  28. 28.
    Branca M, Ciotti M, Santini D et al (2004) p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23:354–365CrossRefPubMedGoogle Scholar
  29. 29.
    Agoff SN, Lin P, Morihara J et al (2003) p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 16(7):665–673CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Ruchi Gupta
    • 1
  • Radhika Srinivasan
    • 2
    Email author
  • Raje Nijhawan
    • 2
  • Vanita Suri
    • 3
  1. 1.Department of PathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of Cytology and Gynecological PathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of Obstetrics and GynecologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations